FDA Approves Dupilumab as First New Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade Dr. Kamal Kant Kohli21 April 2025 9:15 PM ISTThe US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous urticaria (CSU) in patients aged...
Sanofi, Regeneron Pharma secures USFDA approval for Dupixent for chronic spontaneous urticaria Ruchika Sharma19 April 2025 1:15 PM ISTParis: Sanofi and Regeneron Pharma have received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the...
Sanofi Dupixent approved in Japan for COPD Ruchika Sharma30 March 2025 10:00 AM ISTDupixent is intended for injection under the skin (subcutaneous injection) and is given every other week.
USFDA grants priority review to Sanofi-Regeneron Dupixent for bullous pemphigoid Ruchika Sharma20 Feb 2025 12:30 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license...
Sanofi, Regeneron Dupixent sBLA accepted for USFDA review for chronic spontaneous urticaria Ruchika Sharma17 Nov 2024 4:15 PM ISTParis: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the...
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis Ruchika Sharma7 Nov 2024 3:55 PM ISTParis: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in...
FDA approves first biologic treatment for COPD Dr. Kamal Kant Kohli3 Oct 2024 7:30 AM ISTThe US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary...
Sanofi, Regeneron get USFDA nod for Dupixent for COPD Ruchika Sharma29 Sept 2024 12:30 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment...
Dupixent approved in EU as targeted therapy for COPD: Sanofi, Regeneron Pharma Ruchika Sharma3 July 2024 2:00 PM ISTParis: Sanofi and Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has approved Dupixent (dupilumab) as...
USFDA requests additional data on Sanofi Dupixent for treating smoker's lung Ruchika Sharma31 May 2024 3:16 PM ISTParis: Sanofi and Regeneron have announced that the US Food and Drug Administration (FDA) requested additional efficacy analyses on the efficacy...
Dupixent application accepted for priority review by USFDA for COPD with type 2 inflammation Ruchika Sharma23 Feb 2024 4:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
Sanofi Dupixent gets Japenese nod for chronic spontaneous urticaria Ruchika Sharma18 Feb 2024 10:00 AM ISTParis: Sanofi has announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization...
